Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Therapy and Analytical Treatment Interruption in HIV+ Participants Post Allogeneic Stem Cell Transplantation (ITATI)
2019-001461-32Phase 2Completed
- Sponsor
- IrsiCaixa
- Start
- Oct 2019
- Modality
- Anti-infectious Disease mAbs → Neutralizing Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Teropavimab and zinlirvimab in human immunodeficiency virus infection (HIV), sponsored by IrsiCaixa. Primary endpoint: Time to reappearance of HIV-1 viremia after ART interruption. Started Oct 2019; status: completed.
02
Drugs
Teropavimabzinlirvimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2019-001461-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001461-32.